single10MG
SS-31
10MG Protocol
SS-31 10MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; limited data exists beyond 12 weeks
Reconstitution
1.0 mL BAC water
Stabilizes mitochondrial membranes and supports ETC function
Supports ATP production and may reduce pathological ROS
Functional improvements reported in Barth syndrome trial context
Protective effects across multiple preclinical disease models
No significant changes in vital signs or standard labs reported in trials
1
Reconstitution Requirements
- 1.0 mL BAC water
Escalation steps: 2
Defined through week 8
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 5 mg (5000 mcg) | 50 |
| 2 | Weeks 3–8 | 10 mg (10,000 mcg) | 100 |
Inject once daily
8–12 weeks; limited data exists beyond 12 weeks
SS-31 (elamipretide) is described as a cell-permeable tetrapeptide built to target mitochondrial dysfunction at the level of the inner mitochondrial membrane. After administration, it preferentially accumulates where it binds cardiolipin, a membrane phospholipid that helps organize electron-transport-chain (ETC) complexes and maintain cristae structure. By stabilizing cardiolipin–protein interactions, SS-31 is presented as improving ETC efficiency, lowering pathological reactive oxygen species (ROS) generation, and increasing ATP output in high-demand tissues. The protocol summarizes broad preclinical interest across models of cardiac stress, ischemia–reperfusion injury, neurodegeneration, kidney disease, and age-related muscle decline. It also notes human safety observations: across trials, SS-31 has generally been well tolerated without dose-limiting toxicities, with injection-site reactions as the most commonly reported issue and long-term data beyond short study durations being comparatively limited.
Injection-site reactions (redness/itching/transient discomfort)
High incidence of mild injection-site reactions reported in trials
Limited long-term safety data beyond ~12 weeks
No dose-limiting toxicities or serious adverse events directly attributed in published trials (as noted on page)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)